Formulation and Evaluation of Extended Release Floating Matrix Tablet of Eperisone Hydrochloride by Direct Compression Method by Ekta, , et al.
Ekta et al                                                                                                                    Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):86-92 
ISSN: 2250-1177                                                                                  [86]                                                                                 CODEN (USA): JDDTAO 
Available online on 15.06.2019 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted 
non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                                                     Research Article 
Formulation and Evaluation of Extended Release Floating Matrix Tablet of 
Eperisone Hydrochloride by Direct Compression Method 
Ekta1*, Priyanshi Jain1, Shailesh Jain1, Mohammed Azaz Khan2 
1 Patel College of Pharmacy, Ratibad, Bhabdhada Road Bhopal (MP) 462044 
2 Pinnacle Biomedical Research Institute (PBRI), Bharat Scout and Guides Campus, Shanti Marg, Shamla Hills, Bhopal (MP) 462003  
 
ABSTRACT 
Increased complications and costs of marketing of innovative drugs focused greater attention to the development of sustained release (SR) or 
controlled release (CR) drug delivery systems. Delivery systems extended release or controlled release rate can ach ieve predictable and 
reproducible, the extended duration of activity for the short time of life - drugs, reduced toxicity and dose reduction request, the optimized 
therapy and better patient compliance. It is controlled primarily by the type and the proportion of the polymers used in the preparation. 
Eperisone hydrochloride is a centrally acting muscle relaxant acting through poly and mono-synaptic reflexes in the spinal cord, exhibits 
vasodilator effect, increases blood flow and inhibits the pain reflex pathway. The objective of present work was to develop and evaluated oral 
extended release floating matrix tablet of eperisone HCl prepared by the method of direct compression, using hydroxy propyl methyl cellulose 
(HPMC K15, HPMC K4) and PVP K30 as matrix formation polymers. Sodium bicarbonate and citric acid was used as gas generating agents. The 
FTIR spectra of the eperisone HCl and other excipients alone and in combination show the compatibility of the drug and excipients. Nine 
formulations of different polymer percentages were formulated (F1-F9). Pre-compression parameters were evaluated. The influence of matrix 
forming agents and binary mixtures of them on eperisone HCl release was investigated. The formulated tablets were characterized by thickness 
and diameter, drug content, hardness, friability, uniformity of weight, In vitro buoyancy studies and dissolution rate studies. The formulated 
tablets had acceptable physicochemical characters. The data obtained from the in-vitro dissolution studies of optimized batch F7 were fitted in 
different models. The optimized formulation F7 showed 99.45±0.45% drug content and floating lag times of 65±4 sec. Drug release mechanism 
was found to be first order kinetics. Eperisone HCl floating tablets exhibited increased gastric residence time, there by improved bioavailability 
and therapeutic effect of the drug. 
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INTRODUCTION 
Oral controlled drug delivery system provides the 
continuous oral delivery of drugs at predictable and 
reproducible kinetics for a predetermined period throughout 
the course of Gastro Intestinal (GI) transit. Conventional oral 
controlled dosage forms suffer from mainly two adversities 
the short gastric retention time and unpredictable gastric 
emptying time1. A relatively short GI transit time of most 
drug products impedes the formulation of single daily dosage 
forms. Altering the gastric emptying can overwhelm these 
problems. Therefore it is desirable, to formulate a controlled 
release dosage form that gives an extended GI residence 
time. One of the most feasible approaches for achieving a 
prolonged and predictable drug delivery profiles in the 
gastrointestinal tract is to control the gastric residence time 
using gastro retentive dosage forms that offer a new and 
better option for drug delivery2. Dosage forms that can be 
retained in the stomach are called gastro retentive drug 
delivery systems. Gastro retentive systems can remain in the 
gastric region for several hours and hence significantly 
prolong the gastric residence time of drugs. Prolonged 
gastric retention improves bioavailability, reduces drug 
waste and improves solubility for drugs that are less soluble 
in a high pH environment3. Gastro retentive floating tablets 
have been emerged as an efficient means of enhancing the 
bioavailability of many drugs. Rapid gastro-intestinal transit 
could result in incomplete drug release from the drug 
delivery system above the absorption zone leading to 
diminished efficacy of administered dose4. In this present 
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formulation, dual benefits of buoyancy as well as sustained 
action are achieved with an intention to maintain the steady 
state of drug release5. Hydrophilic matrix system is one of 
the easiest approaches for developing modified and 
sustained release dosage forms. A polymer like hydroxyl 
propyl methyl cellulose (HPMC) function as a pH 
independent gelling agent and drug release is shown by 
swelling and erosion mechanism occurring simultaneously 
contributing to overall drug release6.Matrix system is the 
commonly used method for modulating the drug release7. 
The manufacture of matrix tablets by direct compression is 
cheaper, simpler process, broad regulatory acceptance and 
allows flexibility in obtaining desirable release profiles8. 
Eperisone hydrochloride which is chemically known as 4’-
ethyl-2-methyl-3-piperidino propiophenone hydrochloride, 
has chemical formula C17H25NO and belongs to the class of 
muscular relaxants, having molar mass 259.387g/mol9. The 
drug acts by acting on central nervous stem cells providing 
relaxation of both skeletal and vascular smooth muscles10. 
Oral eperisone is effectively used three times daily (t.i.d) at 
dosage regimen of 100 mg. It is well known for use in the 
treatment of muscular spasm, lower back pain, cervical 
spondolysis and in spastic paralysis in terms of 
cerebrovascular disease. The drug is well tolerated at doses 
of with mild GI symptoms involving nausea; abdominal 
cramps, headache and dizziness are the commonly observed 
adverse effects10-12. The drug is rapid absorption after oral 
administration. It has biological half-life of about 1-4.3 hour, 
its rapid elimination rules out risk of accumulation13. The 
present study is to develop a floatable drug delivery system 
of eperisone hydrochloride using hydroxy propyl methyl 
cellulose, PVP K30 for sustained drug delivery and gastric 
retentive property. Thus the study aims to improve the oral 
bioavailability of the drug and to achieve extended retention 
in the stomach which may result in prolonged absorption. 
MATERIALS AND METHODS 
Materials 
Eperisone hydrochloride was obtained as a gift sample from 
Macleod’s Pvt Ltd. (India). Hydroxy propyl methyl cellulose 
(HPMC K4 &K15) was procured from Colorcon Asia Bio 
limited. (India). PVP K30, Citric acid, Magnesium stearate, 
Sodium bicarbonate, Talc, Lactose, were procured from S. D. 
Fine Chem. Ltd, Mumbai, India. All other chemicals and 
solvents used were analytical grades. 
Methods 
Preformulation studies 
Standardization of eperisone HCl by UV-Visible 
spectrophotometry 
Preparation of standard stock solution 
10mg of eperisone HCl was weighed accurately and 
transferred to 10 ml volumetric flask, and the volume was 
adjusted to the mark with the 0.1 N HCl to give a stock 
solution of 1000 ppm or µg/ml. This solution was suitably 
diluted with 0.1 N HCl to obtain a concentration of 15μg/ml. 
The resultant solution was scanned in the range of 200-400 
nm using UV double beam spectrophotometer (Labindia U.V. 
3000 +). 
Standard calibration of eperisone HCl in 0.1N HCl 
100 mg of eperisone HCl was accurately weighed and 
dissolved in100 ml of 0.1N HCl to obtain a concentration of 
1000μg/ml. From the above 10 ml was withdrawn and 
diluted to 100 ml to obtain a concentration of 100μg/ml. 
From this stock solution aliquots of 0.5, 1.0, 1.5, 2.0 and 2.5 
ml were diluted in 10 ml volumetric flask with water to give 
concentrations in the range of 5-25μg/ml, respectively, 
absorbance was measured at 276 nm. 
Identification eperisone HCl by IR  
Identification of eperisone HCl was done by FTIR 
spectroscopy with respect to marker compound. Eperisone 
HCl was obtained as white crystalline powder. It was 
identified from the result of IR spectrum as per specification. 
Preparation of floating matrix tablets of eperisone HCl 
Eperisone HCl matrix floating tablets were prepared by 
direct compression method employing sodium bicarbonate 
and citric acid as gas-generating agent. HPMC and PVP K30 
were used as rate controlling polymers. The concentrations 
of the excipients were optimized as showed in table 1. The 
drug was mixed with the rate retarding polymers and other 
excipients in ascending order of their weights. The powder 
mix was blended for 20 min to have uniform distribution of 
drug in the formulation. Then magnesium stearate and talc 
were added. About 280 mg of the powder mix was weighed 
accurately and fed into the die and compressed using 10 mm 
round surface punches14. The composition of formulation 
was given in table 1. 
 
Table 1 Composition of SR matrix floating tablet of eperisone HCl 
Excipients(mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 
Eperisone HCl 50 50 50 50 50 50 50 50 50 
HPMC K 15 80 100 120 - - - 40 50 60 
HPMC K 4 - - - 80 100 120 40 50 60 
PVP K30 20 20 20 20 20 20 20 20 20 
Citric acid  10 10 10 10 10 10 10 10 10 
NaHCO3 20 20 20 20 20 20 20 20 20 
Mg(C18H35O2)2 5 5 5 5 5 5 5 5 5 
Talc 5 5 5 5 5 5 5 5 5 
Lactose 90 70 50 90 70 50 90 70 50 
Total Weight 280 280 280 280 280 280 280 280 280 
 
Evaluation of eperisone HCl floating matrix tablets 
Pre-compression parameters 
Angle of repose 
The angle of repose of blends was determined by the funnel 
method. The accurately weighed blend was taken in the 
funnel. The height of the funnel was adjusted in such a way 
that the tip of the funnel just touched the apex of the heap of 
the blend. The blend was allowed to flow from the funnel on 
the surface. The diameter and height of the heap formed 
from the blend were measured. The angle of repose was 
calculated using the following formula15. 
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Tan Ѳ= h/r 
Where, “h” is the height of the heap and “r” is the radius of 
the heap of granules. 
Bulk density (BD) 
An accurately weighed powder blend from each formula was 
lightly shaken to break any agglomerates formed and it was 
introduced in to a measuring cylinder. The volume occupied 
by the powder was measured which gave bulk volume. The 
BD of powder blends was determined using the following 
formula16. 
               
                     
                      
 
Tapped bulk density (TBD) 
An accurately weighed powder blend from each formula was 
lightly shaken to break any agglomerates formed and it was 
introduced into a measuring cylinder. The measuring 
cylinder was tapped until no further change in volume was 
noted which gave the tapped volume. The TBD of powder 
blends was determined using the following formula17. 
      
                     
                             
 
Carr’s compressibility index 
The Carr’s compressibility index was calculated from bulk 
density (BD) and tapped density of the blend. A quantity of 2 
g of blend from each formulation, filled into a 10 ml of 
measuring cylinder. Initial bulk volume was measured, and 
cylinder was allowed to tap from the height of 2.5 cm. The 
tapped frequency was 25±2/min to measure the tapped 
volume of the blend. The BD and tapped density were 
calculated by using the bulk volume and tapped volume. 
Carr’s compressibility index was calculated using the 
following formula18,19. 
                                   
                           
              
     
Hausner’s ratio 
It is the measurement of frictional resistance of the drug. 
The ideal range should be 1.2-1.5, it was determined by the 
ratio of tapped density and bulk density. 
HR = Tapped Density/ Bulk Density 
Post-compression parameters 
All the tablets were evaluated for following different 
parameters which includes; 
General appearance  
Ten tablets from different batches were randomly selected 
and organoleptic properties such as color, shape, were 
evaluated. Appearance was judged visually. Very good (+++), 
good (++), fair (+) poor (-), very poor (- -). 
Thickness and diameter  
Thickness and diameter of tablets were determined using 
Vernier caliper. Five tablets from each batch were used and 
an average value was calculated. 
Drug content  
Twenty tablets were taken and amount of drug present in 
each tablet was determined. The tablets were crushed in a 
mortar and the powder equivalent to 100mg of drug was 
transferred to 100ml standard flask. The powder was 
dissolved in 50 ml of 0.1 N HCl and made up to volume with 
of 0.1 N HCl. The sample was mixed thoroughly and filtered 
through a 0.45μ membrane filter. The filtered solution was 
diluted suitably and for drug content by UV 
spectrophotometer at λ max of 276 nm using of 0.1 N HCl as 
blank. 
Hardness  
For each formulation, the hardness of five tablets was 
determined using the Monsanto hardness tester (Cadmach). 
Friability  
From each batch, ten tablets were accurately weighed and 
placed in the friability test apparatus (Roche friabilator). 
Apparatus was operated at 25 rpm for 4 minutes and tablets 
were observed while rotating. The tablets were then taken 
after 100 rotations, dedusted and reweighed. The friability 
was calculated as the percentage weight loss. 
% friability was calculated as follows 
% Friability = (W1 – W2) x 100/W1 
Where W1 = Initial weight of the 10 tablets, W2 = Final 
weight of the 10 tablets after testing. 
Friability values below 0.5-1% are generally acceptable 
Uniformity of weight  
Twenty tablets were randomly selected from each batch 
individually weighed, the average weight and standard 
deviation of 20 tablets was calculated. 
In vitro buoyancy studies 
In vitro buoyancy was determined by floating lag time as per 
the method described by Rosa et al. The tablets were placed 
separately in a 100 ml glass beaker containing simulated 
gastric fluid (SGF), pH 1.2 as per USP. The time required for 
the tablet to rise to the surface and float was determined as 
floating lag time20. 
Dissolution rate studies 
In vitro drug release of the sample was carried out using 
USP- type II dissolution apparatus (Paddle type). The 
dissolution medium, 900 ml 0.1N HCl was placed into the 
dissolution flask maintaining the temperature of 37±0.50C 
and rpm of 75. One eperisone HCl tablet was placed in each 
basket of dissolution apparatus. The apparatus was allowed 
to run for 10 hours. Sample measuring 5 ml were withdrawn 
after every 1 hour up to 10 hours using 10ml pipette. The 
fresh dissolution mediums (370C) were replaced every time 
with the same quantity of the sample and take the 
absorbance at 276.0 nm using spectroscopy. 
Mathematical treatment of in-vitro release data 
The quantitative analysis of the values obtained in 
dissolution/release tests is easier when mathematical 
formulas that express the dissolution results as a function of 
some of the dosage forms characteristics are used. 
1. Zero-order kinetics: The pharmaceutical dosage forms 
following this profile release the same amount of drug by 
unit of time and it is the ideal method of drug release in 
order to achieve a pharmacological prolonged action. The 
following relation can, in a simple way, express this model: 
Qt = Qo + Ko t 
where Qt is the amount of drug dissolved in time t, Qo is the 
initial  amount of drug in the solution (most times, Qo=0) and 
Ko is the zero order release constant. 
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2.  First-order kinetics: The following relation expresses 
this model: 
 
where Qt is the amount of drug dissolved in time t, Qo is the 
initial  amount of drug in the solution and K1 is the zero 
order release constant. 
In this way a graphic of the decimal logarithm of the released 
amount of drug versus time will be linear. The 
pharmaceutical dosage forms following this dissolution 
profile, such as those containing water-soluble drugs in 
porous matrices, release drug in a way that is proportional 
to the amount of drug remaining in its interior, in such way, 
that the amount of drug released by unit of time diminish. 
3. Higuchi model: Higuchi developed several theoretical 
models to study the release of water-soluble and low soluble 
drugs in semi-solid and/or solid matrixes. Mathematical 
expressions were obtained for drug particles dispersed in a 
uniform matrix behaving as the diffusion media. 
 The simplified Higuchi model is expressed as: 
 
Where Q is the amount of drug released in time t and KH is 
the Higuchi dissolution constant. Higuchi model describes 
drug release as a diffusion process based in the Fick’s law, 
square root time dependent. This relation can be used to 
describe the drug dissolution from several types of modified 
release pharmaceutical dosage forms such as transdermal 
systems and matrix tablets with water-soluble drugs. 
4. Korsmeyer-Peppas model: Korsmeyer et al. used a 
simple empirical equation to describe general solute release 
behaviour from controlled release polymer matrices:  
 
Where Mt/M is fraction of drug released, a is kinetic 
constant, t is release time and n is the diffusional exponent 
for drug release. ’n’ is the slope value of log Mt/M  versus 
log time curve. Peppas stated that the above equation could 
adequately describe the release of solutes from slabs, 
spheres, cylinders and discs, regardless of the release 
mechanism. Peppas used this n value in order to 
characterize different release mechanisms, concluding for 
values for a slab, of n =0.5 for fickian diffusion and higher 
values of n, between 0.5 and 1.0, or n =1.0, for mass transfer 
following a non-fickian model. In case of a cylinder n =0.45 
instead of 0.5, and 0.89 instead of 1.0. This equation can only 
be used in systems with a drug diffusion coefficient fairly 
concentration independent. To the determination of the 
exponent n the portion of the release curve where Mt/M  < 
0.6 should only be used. To use this equation it is also 
necessary that release occurs in a one-dimensional way and 
that the system width-thickness or length-thickness relation 
be at least 10. A modified form of this equation was 
developed to accommodate the lag time (l) in the beginning 
of the drug release from the pharmaceutical dosage form: 
 
When there is the possibility of a burst effect, b, this 
equation becomes: 
 
In the absence of lag time or burst effect, l and b value would 
be zero and only atn is used. This mathematical model, also 
known as Power Law, has been used very frequently to 
describe release from several different pharmaceutical 
modified release dosage forms21-23. 
RESULTS AND DISCUSSIONS 
Eperisone HCl was found to be white crystalline powder in 
appearance, odourless and tasteless. Solubility of eperisone 
HCl was freely soluble in methanol, ethanol and water, 
soluble in chloroform and 0.1N HCl, Slightly soluble in 
0.1N NaOH and Insoluble in 7.2 phosphate buffer. The 
melting point of eperisone HCl was 169-171°C and 
percentage of loss on drying, moisture content of eperisone 
HCl was found to be 0.25%, 0.13% respectively. The λ max of 
eperisone HCl was found to be 276 nm by using U.V. 
spectrophotometer (Labindia-3000+) in linearity range 5-25 
µg/ml Fig.1. Identification of eperisone HCl was done by 
FTIR spectroscopy with respect to marker compound. It was 
identified from the result of IR spectrum as per specification 
Fig.2. 
 
Figure 1 Calibration curve of eperisone hydrochloride 
 
Figure 2 IR Spectra of eperisone hydrochloride  
Tablet powder blend was subjected to various pre-
compression parameters Table 2. The angle of repose values 
indicates that the powder blend has good flow properties. 
The bulk density of all the formulations was found to be in 
the range of 0.515±0.25 to 0.565±0.45 (gm/ml) showing that 
the powder has good flow properties. The tapped density of 
all the formulations was found to be in the range of 
0.596±0.74 to 0.636±0.32 showing the powder has good 
flow properties. The compressibility index and Hauser’s 
ratio of all the formulations were found to be ranging 
between 9.364±0.45 to14.869±0.21 and1.103±0.10 
to1.175±0.15 respectively which show that the powder has 
good flow properties.  
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Table 2 Result of pre-compression properties of eperisone hydrochloride tablets blend 
F. Code Angle of repose 
(Ѳ) 
Bulk 
density(gm/ml) 
Tapped 
density(gm/ml) 
Compressibility 
index 
Hausner’s 
ratio 
Eperisone hydrochloride  
F1 36.56±0.25 0.515±0.25 0.598±0.32 13.879±0.12 1.161±0.45 
F2 36.45±0.36 0.526±0.32 0.599±0.25 12.186±0.25 1.139±0.36 
F3 35.65±0.45 0.545±0.14 0.605±0.45 9.917±0.36 1.110±0.25 
F4 35.65±0.25 0.521±0.36 0.612±0.65 14.869±0.21 1.175±0.15 
F5 36.12±0.45 0.532±0.45 0.605±0.14 12.066±0.35 1.137±0.47 
F6 36.45±0.36 0.536±0.36 0.615±0.45 12.845±0.45 1.147±0.98 
F7 36.45±0.58 0.565±0.45 0.636±0.32 11.163±0.74 1.126±0.12 
F8 36.45±0.69 0.542±0.12 0.598±0.48 9.364±0.45 1.103±0.10 
F9 36.45±0.78 0.536±0.32 0.596±0.74 10.067±0.47 1.112±0.32 
 
The results of post-compression parameters such as the 
thickness and diameter, drug content, hardness, friability, 
uniformity of weight, In vitro buoyancy studies and 
dissolution rate studies of the tablets are given in Table 3. All 
the tablets of different batches complied with the official 
requirements of uniformity of weight. The hardness of the 
tablets ranged from 5.1±0.1to 5.8±0.3 kg/cm2 and the 
friability values were less than 0.8% indicating that the 
matrix tablets were compact and hard. The thickness of the 
tablets ranged from 3.12±0.06 to3.61± 0.05mm. All the 
formulations satisfied the content of the drug as they 
contained 98.69±0.23 to 99.45±0.45 % of eperisone HCl and 
good uniformity in drug content was observed. Thus all the 
physical attributes of the prepared tablets were found be 
practically within control. 
 
Table 3 Results of post compression properties of eperisone hydrochloride floating matrix tablets 
F. code Thickness*  
(mm) 
Hardness*  
(kg/cm2) 
Weight 
variation*  (mg) 
Friability* 
(%) 
Drug 
content* (%) 
F1   3.56±0.05 5.2±0.1 280±5 0.856±0.12 98.89±0.21 
F2 3.54± 0.10 5.6±0.2 285±6 0.812±0.15 98.69±0.23 
F3 3.52± 0.05 5.1±0.1 284±7 0.865±0.25 98.78±0.15 
F4 3.45± 0.05 5.6±0.3 286±4 0.878±0.32 99.12±0.47 
F5 3.54± 0.10 5.4±0.2 289±9 0.842±0.25 98.45±0.58 
F6 3.58± 0.06 5.8±0.3 287±5 0.896±0.45 99.12±0.65 
F7 3.59± 0.05 5.3±0.2 284±4 0.845±0.47 99.45±0.45 
F8 3.61± 0.05 5.4±0.3 286±3 0.812±0.52 98.78±0.32 
F9 3.12±0.06 5.6±0.1 289±3 0.856±0.45 98.78±0.45 
*n=3 
Table 4 Results of in-vitro buoyancy study of eperisone 
HCl 
Formulation 
Code 
Floating lag 
times (sec) n=3 
Total Floating 
Time (hrs) 
F1 60±3 >12 
F2 65±2 >12 
F3 63±5 >12 
F4 64±6 >12 
F5 65±4 >12 
F6 68±5 >12 
F7 55±6 >12 
F8 63±7 >12 
F9 64±2 >12 
 
In vitro buoyancy was determined by floating lag time and 
total floating time. Results were given in table 4.  
The tablets were evaluated for in vitro dissolution studies in 
0.1N HCl for 12 hours. The results of in-vitro drug release 
revealed that the eperisone HCl was released in a controlled 
manner from all the formulations where formulation F7 
showed maximum drug release i.e. 99.89±0.32 % at the end 
of 12th hour. The results of release studies of formulations F1 
to F9 are shown in Table 5 and Figure 3. 
 
Table 5 In-vitro drug release study of GRF tablets 
Time  % Cumulative Drug Release (n=3) (Mean ± S.D.) 
(hrs.) F1 F2 F3 F4 F5 F6 F7 F8 F9 
0.5 36.56±0.25 35.65±0.32 33.25±0.21 30.21±0.32 28.98±0.32 26.65±0.36 25.56±0.12 20.25±0.32 15.45±0.32 
1 45.89±0.23 42.56±0.15 40.45±0.14 39.98±0.45 35.45±0.15 30.35±0.45 36.45±0.19 29.98±0.21 22.12±0.15 
1.5 65.54±0.15 60.25±0.54 58.98±0.32 55.45±0.41 51.15±0.45 40.56±0.54 48.98±0.21 45.58±0.41 41.45±0.45 
2 89.32±0.12 85.59±0.65 65.45±0.41 62.14±0.23 60.25±0.65 61.25±0.36 55.65±0.32 50.25±0.47 46.65±0.74 
3 98.78±0.25 96.65±0.12 89.98±0.21 86.65±0.14 82.12±0.42 70.25±0.25 69.98±0.45 61.15±0.65 50.45±0.56 
4   99.89±0.15 95.45±0.32 93.12±0.25 91.65±0.14 83.25±0.45 75.65±0.32 70.25±0.45 55.65±0.65 
6     99.12±0.45 99.45±0.36 99.45±0.65 93.56±0.36 86.69±0.41 75.65±0.32 64.45±0.14 
8           98.78±0.45 95.56±0.25 80.25±0.25 78.89±0.32 
12             99.89±0.32 89.98±0.45 85.23±0.25 
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Figure 3 In-vitro drug release study of GRF tablets 
The in vitro drug release data of the optimized formulation 
F7 was subjected to goodness of fit test by linear regression 
analysis according to zero order, first order kinetic equation, 
Higuchi’s and Korsmeyer’s models in order to determine the 
mechanism of drug release. When the regression coefficient 
values of were compared, it was observed that ‘r’ values of 
first order was maximum i.e. 0.931hence indicating drug 
release from formulations was found to follow first order 
release kinetics Table 6, 7 & Fig. 4,5. 
  
Table 6 In-vitro drug release data for optimized formulation F7 
Time (h) 
Square Root 
of Time(h)1/2 
Log Time 
Cumulative*% Drug 
Release 
Log Cumulative 
% Drug Release 
Cumulative %  
Drug Remaining 
Log Cumulative 
% Drug 
Remaining 
0.5 0.707 -0.301 25.56 1.408 74.44 1.872 
1 1 0 36.45 1.562 63.55 1.803 
1.5 1.225 0.176 48.98 1.690 51.02 1.708 
2 1.414 0.301 55.65 1.745 44.35 1.647 
3 1.732 0.477 69.98 1.845 30.02 1.477 
4 2 0.602 75.65 1.879 24.35 1.386 
6 2.449 0.778 86.69 1.938 13.31 1.124 
8 2.828 0.903 95.56 1.980 4.44 0.647 
12 3.464 1.079 99.89 2.000 0.11 -0.959 
 
 
Figure 4 Cumulative % drug released Vs Time 
 
Figure 5 Log cumulative % drug remaining Vs Time 
 
Table 7 Regression analysis data of eperisone 
hydrochloride floating matrix tablets 
Batch 
Zero Order First Order 
R² R² 
F7 0.817 0.931 
 
CONCLUSION 
The present research work was successful in improving the 
efficacy of eperisone HCl oral therapy as the drug release 
was extended for 12 hours thus reducing dosing frequency 
thereby improving patient compliance. The sustained 
release floating matrix tablets of eperisone HCl were 
prepared by direct compression method. FTIR spectra 
indicated the absence of probable chemical interaction 
between the drug and polymers. Eperisone HCl SR floating 
matrix tablets were formulated with HPMC, PVP K30 and 
citric acid, NaHCO3. Among 9 formulations, F7 is optimized 
based on the cumulative % drug release is 99.89 in 12 hrs. 
The in vitro drug release data was plotted for various kinetic 
models. The R2 value for optimized formulation F7 for first 
order was found to be 0.931. It is evident from the results 
that a matrix tablet of eperisone HCl is a better system for 
twice daily sustained release dosage regimen. Furthermore 
the in-vivo and pharmacokinetic study have to carry out. 
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